An observational, retrospective, multicenter study to assess the efficacy of fingolimod in clinical practice in patients with relapsing-remitting multiple sclerosis

Trial Profile

An observational, retrospective, multicenter study to assess the efficacy of fingolimod in clinical practice in patients with relapsing-remitting multiple sclerosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms NEXT
  • Most Recent Events

    • 27 Jun 2017 Results (n=988) of a pooled analysis of two observational retrospective studies MS SECOND LINE GATE and MS NEXT assessing basal characteristics and effectiveness of fingolimod, presented at the 3rd Congress of the European Academy of Neurology
    • 28 Apr 2017 Results (n=988) of a pooled analysis of two observational retrospective studies (MS SECOND LINE GATE and MS NEXT) assessing safety and tolerability of fingolimod in Spanish clinical practice, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of pooled analysis of two observational retrospective studies (MS SECOND LINE GATE and MS NEXT) presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top